Esomeprazole vs Vonoprazan for GERD in Patients With a Partial Response to a Proton-Pump Inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neurogastroenterology and Motility
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor
Neurogastroenterol. Motil. 2022 Sep 30;[EPub Ahead of Print], J Tack, B Vladimirov, I Horny, CF Chong, J Eisner, R Czerniak, Y TakanamiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.